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Abstract Purpose: Hypertriglyc-
eridemia (hyperTG) is common
among intensive care unit (ICU)
patients, but knowledge about hy-
perTG risk factors is scarce. The
present study aims to identify risk
factors favoring its development in
patients requiring prolonged ICU
treatment. Methods: Prospective
observational study in the medico-
surgical ICU of a university teaching
hospital. All consecutive patients
staying C4 days were enrolled.
Potential risk factors were recorded:
pathology, energy intake, amount and
type of nutritional lipids, intake of
propofol, glucose intake, laboratory
parameters, and drugs. Triglyceride
(TG) levels were assessed three times
weekly. Statistics was based on two-
way analysis of variance (ANOVA)
and linear regression with potential
risk factors. Results: Out of 1,301
consecutive admissions, 220 patients
were eligible, of whom 99 (45 %)
presented hyperTG (triglycerides
[2 mmol/L). HyperTG patients were
younger, heavier, with more brain
injury and multiple trauma. Intake of
propofol (mg/kg/h) and lipids’ pro-
pofol had the highest correlation with
plasma TG (r2 = 0.28 and 0.26,
respectively, both p \ 0.001). Infec-
tion and inflammation were
associated with development of hy-
perTG [C-reactive protein (CRP),
r2 = 0.19, p = 0.004]. No strong
association could be found with
nutritional lipids or other risk factors.
Outcome was similar in normo- and
hyperTG patients. Conclu-
sions: HyperTG is frequent in the
ICU but is not associated with
adverse outcome. Propofol and
accompanying lipid emulsion are the
strongest risk factors. Our results
suggest that plasma TG should be
monitored at least twice weekly in
patients on propofol. The clinical
consequences of propofol-related hy-
perTG should be investigated in
further studies.
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Introduction
Hypertriglyceridemia (hyperTG) is a common metabolic
complication in critical illness [1, 2], but data on its
incidence, risk factors, and impact on outcome are scarce.
The main causes of hyperTG are either genetic or asso-
ciated with secondary pathology such as pancreatitis [3],
sepsis [4], obesity [5], liver failure [6, 7], chronic renal
failure [2, 6, 8], alcohol consumption [9] or type 2 dia-
betes [10, 11]. The type of illness influences the lipid
profile, the magnitude of the changes being proportional
to the severity of the disease [12]; patients with infections
are particularly prone. Despite unclear multifactorial eti-
ology, high lipid levels are considered as a source of
complications in intensive care unit (ICU) patients [2, 6,
8] and should be prevented.
Since the mid 1980s, overfeeding has been identified as
a potential cause of multiple metabolic disorders. The
European Society for Clinical Nutrition and Metabolism
(ESPEN) guidelines recommend a daily energy intake of
25–30 kcal/kg/day in medical and surgical ICU patients,
and even less in the early phase [13]; daily fat intake
should not exceed 0.7–1.5 g/kg to prevent fat overload
[13]. Similarly, exceeding a cumulative glucose intake
of 5 g/kg/day should be avoided to prevent de novo
lipogenesis [13]. Despite these recommendations, a mul-
ticenter study reported a 33 % incidence of hyperTG,
defined as plasma triglycerides (TG) [3 mmol/L, among
hospitalized patients receiving a parenteral daily fat intake
of 0.83 ± 0.37 g/kg [8]. The type of lipid also influences
TG levels: medium-chain triglycerides (MCT) and omega-
3 lipid emulsions are alternatives to long-chain triglycer-
ides (LCT) [6, 7], even if the metabolic advantages
compared with LCT emulsions remain debated [14].
Contrary to parenteral fat intake, enteral fat has rarely been
associated with hyperTG [15]. Critically ill patients fre-
quently require sedation. One of the most popular drugs is
propofol, which is emulsified in lipid solutions. Some
small studies suggest that high doses of propofol may play
a key role in hyperTG [1, 16]. Apart from feeding and
propofol, several drugs influence lipid levels: statins [5]
and insulin [2, 10] decrease TG levels, while heparin [17,
18], b-adrenergic catecholamines [19], and corticosteroids
[2] have been shown to induce hyperTG.
The present study aims to determine the prevalence,
severity, and risk factors of hyperTG in a population of
critically ill patients in order to generate clinical etio-
logical hypotheses and determine whether TG should be
monitored in the ICU.
Patients and methods
This prospective observational study, approved by the
ethic committee of the Vaud Canton, was conducted over
a 7-month period (March–October 2009) in a 32-bed adult
mixed ICU. Individual consent was waived as the lipid
profile monitoring was an integral part of the ICU nutri-
tion protocol [blood sampling three times weekly at 6 am
for determination of TG levels and one time weekly for
cholesterol, high-density lipoprotein (HDL)-cholesterol,
C-reactive protein (CRP), albumin, and transthyretin].
The inclusion criterion was ICU stay C4 days. Exclusion
criteria were: only one determination of TG during the
stay, and patients on oral feeding. Hypertriglyceridemia
was defined as plasma TG level [2 mmol/L [20], severe
hyperTG being defined as TG [5 mmol/L. Patients were
allocated to two groups according to peak TG level:
normo- or hyperTG groups. The patients were classified
according to predefined diagnostic groups, i.e., sepsis
(severe sepsis and septic shock [21] on admission or at
time of hyperTG), acute pancreatitis, diabetes (type 1 and
2), chronic renal failure, and use of statins before and
during hospitalization with specification of preexisting
dyslipidemia. The control group was constituted by
patients without these pathologies.
Data were extracted from the the clinical information
system (CIS; MetaVision iMDSoft, version 5.45.5403;
Tel Aviv, Israel), which is customized to provide detailed
composition and quantities of the enteral and parenteral
feeding solutions including the respective amount of LCT
and MCT [22]. The nonnutritional substrate intakes were
also integrated in the computations, whether coming from
glucose 5 % or the propofol lipid emulsions. The cumu-
lative energy intake included nutritional (i.e., enteral =
EN, parenteral nutrition = PN) and nonnutritional energy
intake (i.e., glucose or lipid vehicle).
Patient data included age, admission weight, ideal
body weight (IBW), body mass index (BMI), type of
admission (surgical or medical), diagnosis, and mortality
(ICU and hospital). Recorded medications included stat-
ins (type and dose), heparin, insulin, catecholamines,
corticosteroids (hydrocortisone equivalents), and propofol
(mg/day and mg/kg/h). Propofol is delivered under three
forms: 2 % solution for continuous sedation (Disopri-
van, Astra Zeneca, Zug, Switzerland; Propofol MCT
Fresenius, Fresenius Kabi, Oberdorf, Switzerland) and
1 % solution for short procedures (Disoprivan). The
differences in fat content are integrated in the CIS.
All plasma TG values were recorded to enable the
calculation of ‘‘delta-TG’’ (the difference between the
lowest and highest TG values), including in normoTG
patients; the delta-TG value hence differs from the peak
value. Only the highest TG value was considered for the
analysis of the temporal relationship with specific risk
factors.
Laboratory data included alanine aminotransferase
(ALT), aspartate aminotransferase (AST), albumin, pan-
creatic amylase, direct bilirubin, creatinine, gamma-
glutamyl transpeptidase (c-GT), glycemia, lipase, alkaline
phosphatase, procalcitonin, CRP, thromboplastin time,
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and urea. Triglycerides, cholesterol, and HDL-cholesterol
were analyzed as independent variables.
Clinical management
The ICU’s feeding protocol recommends an energy target
of 25 to 30 kcal/kg/day for medical and surgical condi-
tions, respectively (with downregulation in elderly and
obese) and indirect calorimetry after 1 week [23]. Con-
tinuous EN is encouraged, PN being limited to
gastrointestinal failure; all feeding solutions contained
either MCT/LCT mixtures or structured lipids (no fish
oil). The sedation protocol based on the recommendations
of the European Society of Intensive Care Medicine dis-
courages use of high-dose propofol ([4 mg/kg/h) while
integrating daily sedation pauses. The ICU glucose con-
trol protocol is nurse driven and aims at blood glucose
values between 6 and 8 mmol/L (determined by blood gas
analyzer).
Analytical methods
Enzymatic methods were used to determine triglycerides
(GPO-PAP), cholesterol (CHOD-PAP), and HDL-cho-
lesterol (CHOD-PAP, HOMOGENE PEG). For other
determinations, standards methods were used; the labo-
ratory is ISO certified.
Statistical analysis
Results are expressed as median and interquartile range or
as number of subjects and percentage, as well as mean ±
standard error of the mean (SEM) in Fig. 1. Variables
were tested for normality, and TG values were found to be
nonnormally distributed; therefore, log values were used
for further analysis. The factors associated with hyperTG
were further analyzed using simple and multiple linear
regressions. The groups of patients at risk were compared
post hoc with the control group using Dunnett’s test. The
odds ratios for hyperTG and the 95 % confidence inter-
vals were calculated using the method described by
Armitage and Berry [24]. The statistical packages used
were JMP V8.1 (SAS Institute, Cary, NC, USA) and R (R
Foundation, version 2.15.1) open-source software. Sta-
tistical significance was considered at the level p \ 0.05.
Results
During the study period, 1,301 patients were admitted to the
ICU, of whom 308 (23.7 %) were eligible for the study; 88
patients were excluded, due to eating regular meals
(n = 50), or having only one TG determination (n = 38)
and 38 patients with only one TG determination.
The clinical characteristics of the 220 patients are
summarized in Table 1. All patients required mechanical
ventilation, and stayed for 10.4 days as a median in the
ICU. Ninety-nine patients (45 %) developed hyperTG.
The hyperTG patients were younger, had lower Simplified
Acute Physiology Score II (SAPS II) scores, and stayed
longer in the ICU, while mortality did not differ from
normoTG. The pathologies were unevenly distributed,
with more cardiac pathologies and less trauma in the
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normoTG group (p = 0.04). Among the predefined risk
categories, those poorly represented were the following
(n = 11): diabetes (n = 7), renal failure (n = 3), and
pancreatitis (n = 1). Septic patients (n = 124) were
observed in all diagnostic categories and were overrep-
resented in the hyperTG group (n = 75; 76 %).
Altogether 70 patients received statins either before
or during their stay, 12 for dyslipidemia, 11 after
acute myocardial infarction, and the others for unclear
reasons.
Feeding
Twenty-four hours before the peak TG value, 136 patients
(61.8 %) were under EN, 36 (16.4 %) were under PN,
29 (13.2 %) were receiving combined nutrition (i.e.,
EN ? PN), and 19 were unfed. Energy intakes were on
the hypocaloric side (median 16.8 kcal/kg/day). The hy-
perTG group received significantly more fat, while
remaining within recommended ranges; energy and glu-
cose intakes did not differ. The higher fat load in the
hyperTG group resulted mainly from propofol fat.
Plasma triglycerides
TG values varied during the stay in all patients, but varied
significantly more in those patients developing hyperTG.
The latter patients started with higher TG reference val-
ues, although the majority of these values were within
normal ranges.
HyperTG occurred after 7 days as a median, and after
4 days on higher-dose propofol. Figure 1 shows the sig-
nificant differences in propofol delivery between the two
groups, causing a significantly larger fat delivery (daily
propofol and fat dose: r2 = 0.222, p \ 0.0001).
While total cholesterol did not differ significantly,
HDL-cholesterol was lower in the hyperTG patients
(0.46 ± 0.30 versus 0.79 ± 0.37 mmol/L, p \ 0.0001).
Low total and HDL-cholesterol were both associated with
hospital mortality (p \ 0.05).
Pathologies and drugs
No significant relationship between comedications (insu-
lin, heparin, catecholamines, corticosteroids, or other
drugs) and TG levels was observed.
Among patients on statins, 26 (37.1 %) developed
hyperTG versus 48.7 % in those not receiving statins
(p = 0.108, NS). Patients on statins received less propo-
fol than those without. They presented significantly fewer
infections (41.4 versus 63.3 % p = 0.0023) but no dif-
ference in mortality (9 versus 10 % ICU mortality).
Table 2 summarizes the results of the single regression
analysis between TG levels and the various risk factors.
Correlation between plasma TG and total cholesterol was
fair (r2 = 0.41, p \ 0.001).
Infection, inflammation (CRP), and propofol were
significantly associated with hyperTG, by both single and
multiple regressions (Table 3); sepsis was highly signifi-
cantly associated with this metabolic alteration.
Propofol intake
Altogether 144 patients (65.5 %) received propofol,
ranging from 0.04 to 5.83 mg/IBW/h before their peak
TG value. Patients with brain injury and multiple trauma
received significantly higher doses of propofol (Table 1).
A strong association between TG levels and propofol dose
(mg/kg/h) and the propofol lipid vehicle was observed
(r2 = 0.28 and 0.26, respectively, p \ 0.001). The med-
ian dose of propofol associated with hyperTG was
2.04 mg/kg/h. The magnitude of the TG increase (del-
taTG) was influenced by the cumulated dose of propofol
before the peak (r2 = 0.038, p = 0.0037), the propofol
dose/kg/h (r2 = 0.061, p = 0.0002), but less by number
of days on propofol before the peak (r2 = 0.020,
p = 0.034) or lipid dose (r2 = 0.027, p = 0.013).
Total cholesterol and HDL-cholesterol levels were
unaffected by the propofol dose.
Table 2 Correlation between selected daily parameters and peak
triglyceride concentration
Parameter term Pearson’s
coefficient
(r2)
Significance
Propofol (mg/kg/h) 0.28 \0.001
Lipids from propofol (g/kg/day) 0.26 \0.001
CRP (mg/L) 0.19 0.004
Total lipid intake (g/kg/day) 0.14 0.024
Cumulative glucose intake
(g/day)
0.12 NS
Cumulative glucose intake
(g/kg/day)
0.11 NS
Cumulative energy intake
(kcal/kg/day)
0.09 NS
LCT ? MCT parenteral lipids
(g/kg/day)
0.07 NS
Total LCT intake (g/kg/day) 0.04 NS
LCT ? MCT enteral lipids
(g/kg/day)
0.04 NS
Insulin dose (UI/24 h) 0.02 NS
Propofol dose is the mean dose per ideal body weight per day
between admission and peak TG value
Cumulative glucose and energy intakes: integration of intakes from
admission
LCT long-chain triglycerides, MCT medium-chain triglycerides,
TPN total parenteral nutrition
1994
Lipid intake
Fat from feeding (EN ? PN) did not differ, while intra-
venous fat from propofol was proportional to the propofol
dose and significantly higher in the hyperTG patients
(Fig. 1). The correlation between lipid intake and TG
levels was significant but less than that of propofol.
Discussion
The present study confirms that hyperTG is very common
in critically ill patients, being observed in 45 % of
patients requiring at least 4 days of ICU treatment. It
takes a few days to develop, seven as a median. The
propofol (dose and lipid vehicle) and the infection were
the factors showing the strongest association with this
metabolic complication. The incidence of hyperTG varies
widely in the literature, ranging from 18 to 38 % [1, 2].
These differences are attributable to the variability of the
patient cohorts, the treatments, and the definition of hy-
perTG, ranging from [1.7 mmol/L to C5.65 mmol/L [1,
2]. Indeed, the proportion of patients in our cohort pre-
senting values exceeding 5 mmol/L was only 4.5 %.
The observed changes in TG levels were not a unified
process, but the conjunction of infection and high-dose
propofol (as shown in Fig. 2) was a frequent pattern. High-
dose propofol resulted in increased fat delivery. The
association between the propofol dose (1 or 2 %) and the
TG concentrations has been previously investigated, but
the time relationship has been inconsistent. McLeod et al.
Table 3 Plasma triglyceride values and propofol doses of the different diagnostic categories
Triglyceridemia
(mmol/L)
Median propofol
dose (mg/kg/h)
All (n = 220) NormoTG patients
(n = 121)
Odds ratio
(95 % CI)
Control group 1.6 (1.3; 2.3) 0.8 (0.2; 1.7) 73 50 0.4 (0.2–0.8)
Other groups at risk 1.4 (1.2; 1.6) 0.3 (0; 0.8) 11 10 0.1 (0–0.9)
Dyslipidemia 1.2 (1.1; 1.5) 0.6 (0.1; 0.9) 12 12 NA
Sepsis 2.4 (1.7; 3.4)a 0.9 (0.1; 2) 124 49 4.6 (2.5–8.2)
Results presented as median (interquartile range)
Other groups at risk are composed of diabetes mellitus, chronic renal failure, and pancreatitis
a Values significantly different from the control group (p \ 0.001)
Fig. 2 Example of plasma
triglyceride evolution with the
cumulated daily dose of the
different lipid types over time
(EN enteral nutrition, PN
parenteral nutrition). The total
daily propofol dose (dashed
line, hyperTG reference). In this
case, events prior to day 8
(highest TG peak) were
considered for analysis
1995
[25] found a similar association in 30 ICU patients who
received exogenous lipids only from propofol over 50 h.
HyperTG induced by propofol has mainly two possible
causes: the most likely is the fat emulsion vehicle itself,
and possibly but less likely the inhibition of metabolism of
fatty acids in the mitochondria [26–28] caused by
uncoupling of oxidative phosphorylation and energy pro-
duction [29]. Some authors have reported that hyperTG
was not directly associated with the total amount of
infused lipids [1, 8], which is interesting as the propofol’s
LCT emulsion is identical to that used for PN [26, 30].
Moreover, Theilen et al. [16] failed to demonstrate the
superiority of a LCT/MCT propofol formulation (sup-
posed to reduce the occurrence of hyperTG), suggesting
that lipids associated with propofol were not responsible
for the TG alterations. However, prolonged administration
of propofol, which amounted to 15.9 % of the total fat
delivery in our study, may require adjustment of PN or EN
to avoid overfeeding during propofol sedation [31]. From
a metabolic point of view it is important to be aware that a
very common 200 mg/h propofol sedation rate (i.e.,
4,800 mg of propofol/24 h) results in the delivery of 24 g
of fat with a 2 % solution, and 48 g with a 1 % solution.
Importantly, as our ICU uses two different concentrations,
there is a slight variation of the propofol-related lipid
intake, explaining the stronger correlation with propofol,
directly followed by the lipid dose.
Parenteral lipid intake is known to exacerbate hyperTG
during acute illness [2, 6]. Guidelines for parenteral fat
intake [13] were respected. Enteral fat is efficiently
absorbed, and high doses might alter the lipid profile in
case of long-term EN [32], but no association with hy-
perTG was observed in our cohort. This is probably
explained by the use in our hospital of MCT/LCT-based
EN solutions, reducing its impact on TG. Our data confirm
that hyperTG does not occur when maximal nutritional lipid
intakes are respected, the propofol remaining a specific
determinant of hyperTG. Among lipids, MCT-containing
emulsions seem to be associated with less hyperTG [2, 33],
although this remains controversial [14]; as the number of
patients on MCT-propofol was low, we could not confirm
such a benefit.
Overfeeding by any route with glucose or/and fat is a
common cause of hyperTG [34], which was not observed
in our cohort where overfeeding was an exception. All
patients were monitored daily to prevent overfeeding, and
the energy target was frequently verified by indirect cal-
orimetry. Our CIS shows the cumulated glucose dose
from both enteral and intravenous routes, thereby
enabling avoidance of exceeding the maximal oxidation
capacity of 5 mg/kg/h [13] and the risk of de novo lipid
synthesis [35].
The strong association of TG values with CRP confirms
that the acute-phase response causes significant changes to
the lipid metabolism [25]. Infection was present in 75.8 %
of the patients at the time of hyperTG; the conjunction of
an inflammatory response with an elevated propofol dose
seems to increase the risk of developing hyperTG.
There was no increase in mortality with hyperTG, but
with modest hyperTG (only ten patients had values
[5 mmol/L) the impact on outcome is uncertain. Cur-
rently, clinical consequences of acute and transient
hyperTG remain poorly known, although cases of acute
pancreatitis, fatty liver, delayed awakening, retinal lipe-
mia [2, 6, 8], and elevated mortality particularly in
association with hypocholesterolemia [36] have been
described. An increased risk of infection by disruption of
the reticuloendothelial system [2, 33], coagulopathy [25],
neurological disturbance or respiratory failure [2] have
also been reported, none of which occurred in our patients.
Seventy patients (32 %) were on statins: hyperTG was
as frequent in these patients as in those without. They had
received smaller doses of propofol, and importantly they
suffered significantly fewer infectious episodes
(p = 0.0023). At a smaller scale these data are in line
with the results of a recent case–control study including
7,223 cases of pneumonia (out of 71,000 hospital
admissions) which showed that use of statins decreased
pneumonia risk and 30-day mortality [37]. However, the
effects of statins on lipid metabolism are pleiotropic, and
they are not first-line treatment for hyperTG; absence of
impact on TG levels is therefore not surprising.
Limitations of the study
The principal limitation of this prospective, noninter-
ventional study is the modest size of the cohort, which
limits the analysis of the risk factors (n = 220, 45 %
hyperTG); the low number of patients suffering the pre-
defined risk pathologies precludes drawing strong
conclusions. However, the small number of observations
has to be weighed against the inclusion of very sick
patients with median stay of 10 days and 18.6 % hospital
mortality, and the very complete metabolic calculation
available in the database. The high proportion of patients
receiving the sedative drug propofol nevertheless enables
analysis of the impact of this specific drug on the risk of
developing hyperTG. With the presence of sepsis, it was
the strongest determinant of hyperTG. The most likely
explanation is that the other factors have a lesser impact
on lipid metabolism in the critically ill.
Another limitation is the wide spectrum of pathologies
present in the cohort, and presumably of their genetic
characteristics; both modulate the metabolic responses to
feeding and to sepsis. In the absence of more information,
this aspect cannot be explored.
1996
Conclusions
HyperTG is frequent during critical illness, affecting
45 % of the present cohort; TG values remained below
5 mmol/L in the majority of the patients. Although this
alteration was not associated with any worsening of
outcome, the variability of the response justifies moni-
toring of TG levels in case of propofol sedation, as
propofol was the external factor most strongly associ-
ated with hyperTG. Propofol may be a surrogate
though, and this study could not establish whether it
was the drug itself or the lipid vehicle that favored
hyperTG. The simultaneous presence of an infection
reinforced the TG increase, confirming the impact of the
acute-phase response on lipid metabolism. On the other
hand, moderate nutritional fat intakes (enteral or par-
enteral) do not cause this alteration. The TG levels of
patients sedated with propofol should therefore be reg-
ularly monitored, probably two to three times weekly.
Finally, the role of propofol should be further investi-
gated, and clinical consequences of hyperTG remain to
be established.
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